[naviga:h3]U.S. approves new lymphoma drug[/naviga:h3]

U.S. regulators have approved a new treatment for people with a rare form of non-Hodgkin lymphoma.

The Food and Drug Administration on Tuesday granted accelerated approval to AstraZeneca PLC’s Calquence for people with mantle cell lymphoma after chemotherapy or other treatments fail. The British drugmaker is now conducting further testing required by the FDA to confirm the drug’s benefits and risks.

Calquence, also known as acalabrutinib, works by blocking an enzyme needed by the cancer to multiply and spread.

Patients take two capsules a day. The drug will cost about $14,260 per month without insurance, according to AstraZeneca.

[naviga:h3]U.S. home prices rose in August[/naviga:h3]

WASHINGTON — U.S. home prices rose sharply in August from a year ago, a trend that is thwarting many would-be buyers and potentially slowing sales.

The Standard & Poor’s CoreLogic Case-Shiller national home price index, released Tuesday, increased 6.1 percent in August from a year earlier. That’s higher than the 5.9 percent annual gain in July. In nine of the 20 cities tracked by the index, yearly price gains in August were faster than in July.

Fewer Americans are selling their homes, and builders aren’t putting up enough new houses to meet burgeoning demand. Mortgage rates remain at historically low levels, making it easier to afford higher costs. That has resulted in rising prices even as sales have slipped this year.

Sales of existing homes ticked up in September after falling for three months. Still, sales have fallen 1.5 percent from a year ago, according to the National Association of Realtors, the first year-over-year decline since July 2016.

[naviga:h3]U.S. settles pollution case with Exxon[/naviga:h3]

DALLAS — Exxon Mobil settled violations of the clean-air law with the Trump administration by agreeing to pay a $2.5 million civil penalty and spend $300 million on pollution-control technology at plants along the Gulf Coast.

Federal officials said Tuesday that the settlement will prevent thousands of tons of future pollution, including cancer-causing benzene, from eight petrochemical plants in Texas and Louisiana.

Some environmentalists criticized the settlement as insufficient punishment for years of violations by the giant oil company, while others said it addressed excess burning or flaring of gas, a major pollution problem at refineries and chemical plants.

The deal with the U.S. and Louisiana settles allegations that Exxon violated the federal Clean Air Act by releasing excess harmful pollution after modifying flaring systems at five plants in Texas and three in Louisiana. The allegations date back more than a decade.

Exxon said it will install and increase efficiency of the flaring systems and monitor for benzene outside four of the plants. U.S. officials said the deal will cut emissions of toxic pollutants including benzene by 1,500 tons a year and reduce release of other chemicals by thousands of tons.